A Short Squeeze Could Send This Little-Known Biotech Stock Soaring

Spyre Therapeutics (SYRE) has strong technical momentum and is trading at a new 52 week high. SYRE maintains a 100% “Buy” opinion from Barchart. Shares are up more than 50% in the past month. High short interest at 24% of the float is reason for caution, yet a potential short squeeze could drive further upside. Today’s Featured Stock Valued at $2.6 billion, Spyre Therapeutics (SYRE) is a biotechnology company aiming to create inflammatory bowel disease products by combining antibody engineering, ...